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Abstract——Optogenetic strategies to control genet-
ically distinct populations of neurons with light have
been rapidly evolving and widely adopted by the
neuroscience community as one of the most important
tool sets to study neural circuit function. Although
optogenetics have already reshaped neuroscience by
allowing for more precise control of circuit function
compared with traditional techniques, current limita-
tions of these approaches should be considered. Here,
we discuss several strategies that combine optogenetic
and contemporary pharmacological techniques to
further increase the specificity of neural circuit
manipulation. We also discuss recent advances that
allow for the selective modulation of cellular function
and gene expression with light. In addition, we outline
a novel application of optogenetic circuit analysis
for causally addressing the role of pathway-specific
neural activity in mediating alterations in postsynaptic
transcriptional processing in genetically defined
neurons. By determining how optogenetic activation
of specific neural circuits causally contributes to
alterations in gene expression in a high-throughput
fashion, novel biologic targets for future pharmacological
intervention may be uncovered. Lastly, extending
this experimental pipeline to selectively target
pharmacotherapies to genetically defined neuronal
populations or circuits will not only provide more
selective control of neural circuits, but also may lead
to the development of neural circuit specific
pharmacological therapeutics.
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The field of optogenetics, termed for its use of light
to modulate function within genetically defined pop-
ulations of neurons, has evolved at an unprecedented
pace since the initial introduction and expression of
microbial opsin genes in mammalian neurons to permit
the precise control of neural activity on a physiologi-
cally relevant, millisecond timescale (Boyden et al.,
2005). Optogenetic strategies were rapidly adopted
to investigate the underlying neural circuit mecha-
nisms of many diverse processes, including somato-
sensation, sleep, fear, reward, and synaptic plasticity
(Adamantidis et al., 2007; Huber et al., 2008; Zhang
et al., 2008; Johansen et al., 2010; Tsai et al., 2009; Tye
et al., 2011). Optogenetics permits greater specificity
and precision for the systematic dissection of neural
circuit mechanisms over established neuroscience
techniques (i.e., electrical stimulation, lesion/ablation,
and classic pharmacological manipulations) while
circumventing many of the limitations of conventional
methods. Although the enthusiasm for optogenetic
tools is well deserved, these methods also have some
inherent limitations. We propose that the specificity of
optogenetic manipulations is enhanced when used in
combination with pharmacological methodologies. Fur-
thermore, we outline an innovative future application,
which may produce clinically relevant information about
neural circuit dysfunction, by experimentally perturbing
neural activity and assaying the resulting transcrip-
tional changes in postsynaptic neurons. When integrated
with next-generation RNA sequencing technologies for
high-throughput transcriptome analysis, determining
how neural circuit activity induces neuroadaptive
changes in the transcriptional landscape of genetically
defined postsynaptic neurons is within reach. In this
way, the neural circuit and cell-type specificity of
optogenetic analysis can be leveraged in support of
pharmacogenetic research efforts and accelerate the
discovery of novel biologic targets, to which future small
molecule pharmacotherapies that act in a cell-type and
neural circuit specific manner can be applied.
New research approaches to develop therapeutics
that more effectively treat neuropsychiatric and neu-
rologic diseases are needed. These debilitating disor-
ders exact a huge cost both in terms of suffering and
daily life disruption to those afflicted individuals and
as an economic burden to society in the form of lost
productivity and high treatment cost for these chronic
conditions (Kessler et al., 2005; Pillay and Stein, 2007).
Despite the need for novel treatments, many pharma-
ceutical companies have retreated from psychiatric
disease drug development because of the perceived risk
of investing in complex diseases with incompletely
understood pathologic mechanisms (Karayiorgou et al.,
2012). At the same time, the dominant pharmaceuticals
prescribed for anxiety-related, mood, and psychotic dis-
orders fail to produce measurable improvements for a
large percentage of individuals and carry a high po-
tential risk of adverse effects. In addition, although we
have a general mechanistic understanding of the effect
of pharmacotherapy on different neurotransmitter
systems in the brain, a significant gap remains in our
knowledge of the precise neural and circuit-specific
alterations that manifest in neuropsychiatric disorders
and how pharmacological treatments specifically alter
neural circuit function. The aim of this review is to
highlight research that exploited the strengths of
optogenetic strategies to investigate neural circuit
function relevant to neuropsychiatric disease and to
outline a novel experimental approach that integrates
optogenetics and RNA sequencing technologies to pro-
vide new perspectives on the mechanistic underpin-
nings of neurologic disorders that may translate into
novel treatments.
II. Optogenetics Overview
Neuroscience has traditionally relied on lesion/
ablation, electrical stimulation, and pharmacological
activation and inactivation to decipher relationships
between neural function and behavior. Although essen-
tial for defining basic neuroanatomical and functional
relationships between brain and behavior, these techni-
ques have fundamental limitations that preclude their
use to discern cell-type or pathway-specific function in
a behavioral response. Optogenetic manipulations cir-
cumvent many of the weaknesses of traditional methods
by enabling precise cell-type and circuit-specific in-
vestigation of neural function. A comprehensive over-
view of the entire field of optogenetics is beyond the
scope of this review; therefore, we direct the reader to
recent reviews that thoroughly document the history
and development of the field and provide the requisite
conceptual foundation to design and conduct research
implementing these methods (Zhang et al., 2010;
Bernstein and Boyden, 2011; Fenno et al., 2011; Yizhar
et al., 2011a; Tye and Deisseroth, 2012). Here, we
selectively highlight the principal strengths of optoge-
netic manipulations to uncover circuit level mechanisms
relevant to neuropsychiatric disorders.
A. Strengths of the Optogenetic Approach
The novel research approach that is the central to this
review aims to achieve the ultimate goal of identifying
candidate genes or proteins to target with novel cell-type
and circuit-specific pharmacotherapies for neuropsychiatric
ABBREVIATIONS: AAV9, adeno-associated virus serotype 9; BLA, basolateral amygdala; ChR2, channelrhodopsin-2; DA, dopamine; FS,
fast-spiking inhibitory; NAc, nucleus accumbens; PFC, prefrontal cortex; RNA-seq, RNA-sequencing; sCRACM, subcellular ChR2-assisted
circuit mapping.
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disorders. Several critical advances of the optogenetic
approach, which we briefly review below, have enabled
neural circuit function relevant to neuropsychiatric dis-
orders to be investigated with greater specificity and
precision (Fig. 1).
1. Cell-Type Specificity. Genetic targeting strategies
to introduce light-gated opsins into neuronal populations
to selectively manipulate them represent a principal
advance of optogenetic approaches. Neural tissue com-
prises a heterogeneous mixture of phenotypically diverse
cell types that vary with respect to their morphologic,
physiologic, synaptic, and molecular properties. Because
of this complexity, parsing the specific contribution of
any distinct neuronal population embedded within a
network of heterogeneous cell types was formerly an
insurmountable challenge. Before the introduction of
optogenetic techniques, the tools available to record and
manipulate neural activity nonspecifically altered ac-
tivity within a broad volume of tissue, including fibers of
passage, and were unable to discriminate between
functionally distinct cell types. The optogenetic target-
ing of fast-spiking inhibitory (FS) interneurons in the
mammalian neocortex exemplifies the strength of
modulating activity in a functionally important and
genetically distinct neuronal subtype. The cytoarchitec-
tonically diverse neocortex contains many neuronal sub-
types, including several phenotypically distinct classes
of inhibitory interneurons and excitatory pyramidal
neurons that each serve a specialized functional role
in maintaining overall circuit activity (Freund, 2003;
Markram et al., 2004; Isaacson and Scanziani, 2011). Of
importance, cortical inhibitory interneuron dysfunction
has been heavily implicated as a candidate neural
mechanism underlying the manifestation of symptoms
Fig. 1. Strengths of the optogenetic approach for investigating neural circuit function. (A) Optogenetic tools permit activity in genetically defined cell
types within complex circuits to be modulated by light without affecting nearby cell populations of a different genetic lineage. (B) Delivery of light to
axon fibers at the projection targets of a genetically defined neuronal population permits the investigation of synaptic function in an input-specific
fashion. (C) The spatiotemporal precision of light allows activity within specific neuronal populations to be driven with physiologically relevant
millisecond precision to test the causal role of specific patterns of electrical activity for encoding information or driving a behavioral response. (D) The
temporal specificity of optogenetic manipulations also allows for the time-locked activation or inhibition of specific neural pathways in vivo during
precise moments of a behavioral sequence or during presentation of specific environmental cues, such as tone-light–conditioned stimuli or delivery of
aversive shocks. The colored bar depicts the stages of a hypothetical fear-conditioning experiment, where white is the variable inter-trial interval,
yellow is the tone-light–conditioned stimulus presentation, and red represents the shock delivery phase of the experiment.
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in psychiatric disorders, such as schizophrenia, autism,
and various intellectual disorders (Rubenstein and
Merzenich, 2003; Benes, 2010; Uhlhaas and Singer,
2010; Yizhar et al., 2011b; Marin, 2012). More specifi-
cally, dysfunctional circuit mechanisms within the FS
interneurons that selectively express the calcium-
binding protein, parvalbumin, are hypothesized to
underlie a range of symptoms of these neuropsychiatric
diseases. Optogenetic manipulations have allowed the
functional role of FS interneurons in normal cortical
circuit processing to be probed more specifically (Cardin
et al., 2009; Sohal et al., 2009). Targeted delivery of light
to optically activate the parvalbumin-positive FS neu-
rons enhanced cortical network oscillations in the
gamma band, which causally affected sensory process-
ing and signal transmission within cortex (Cardin et al.,
2009; Sohal et al., 2009). These studies provided the
first evidence that a specific cortical cell type implicated
in the pathogenesis of neuropsychiatric disorders could
be selectively modulated to test causal relationships
between brain function and behavior.
2. Temporal Specificity. The ability to deliver pre-
cise activation or inhibition events to defined neural
circuit elements at a millisecond timescale, which is
consistent with the temporal dynamics of endogenous
neural activity, represents the second key strength of
optogenetic manipulations. Although neural circuit
function is temporally modulated over a range of time
intervals, the moment-to-moment processing of sen-
sory cues and adaptive behavioral responses are
mediated by rapid electrical and synaptic signals that
occur on a millisecond timescale. Therefore, tools to
measure and manipulate electrical activity and synap-
tic neurotransmission with physiologically relevant
precision are essential to understand the neural basis
of normal and maladaptive behavior. Traditional
electrophysiological tools operate with sufficient tem-
poral resolution but nonselectively activate large
volumes of tissue, including fibers of passage and
heterogeneous cell types, making the unambiguous
interpretation of electrical recordings a challenge.
The precise temporal control of neural activity
enabled by optogenetic tools has been capitalized on
with two types of experiment that each has distinct
advantages for establishing causality between activity
in specific neural circuits and behavioral consequences.
First, optogenetics allow for neurons to be activated at
consistent firing rates across a range of frequencies.
This is important because, historically, electrical
stimulation studies have shown that neuronal sub-
types are capable of firing over a broad range of
frequencies and that specific neuronal populations
encode information by changing their firing rate. For
example, dopaminergic neurons of the ventral tegmen-
tal area (VTA) have two characteristic firing patterns:
a low-frequency tonic activity (;3–8 Hz) and a higher
frequency phasic burst firing pattern (;10–20 Hz)
(Grace and Bunney, 1984a,b). The phasic bursting
mode was hypothesized to encode cue saliency and
reward prediction errors based on traditional electro-
physiological correlations (for review see Schultz,
1997; Wanat et al., 2009), but the ability to mimic this
firing pattern in vivo selectively and exclusively in
dopaminergic neurons of the VTA required an optoge-
netic approach. Selective stimulation of VTA dopamine
neurons in a burst-like fashion was sufficient to produce
reward-seeking behavior, whereas tonic stimulation
patterns did not (Tsai et al., 2009). In addition, phasic
optogenetic stimulation of dopamine neurons reinforces
behavioral responding (Witten et al., 2011). Collectively,
these studies highlight that controlling patterned neural
activity in genetically defined neurons is a key advan-
tage of implementing these tools to study neural circuits
and behavior.
Temporally precise optogenetic manipulations also
permit patterned activation of neural circuit elements
time-locked to discrete environmental events or at key
moments during behavior. Our group has used this
approach to study how activation or inhibition of key
neural circuits within the mesolimbic system control
conditioned rewarding or aversive behavioral pheno-
types (Stuber et al., 2011; van Zessen et al., 2012;
Stamatakis and Stuber, 2012). To accomplish this, we
have applied optogenetic stimulation or inhibition time-
locked to salient events, such as presentation of reward
predictive cues. Restricting optogenetic manipulations to
a brief time window surrounding an event tests whether
neural circuit activity at a key time point is sufficient or
necessary to produce a particular behavioral outcome.
This strategy also allows for testing of whether op-
togenetic manipulations of the same duration outside
a given time point can produce similar or different
results. Because many neuropsychiatric disorders result,
at least in part, from an underlying circuit dysfunction
that leads to overactive emotional responses to salient
environmental cues, the temporal precision of time-
locked optogenetic activations should enhance our un-
derstanding of the underlying neural mechanisms of
these diseases (Bishop, 2007; Hartley and Phelps, 2010;
Koob and Volkow, 2010; Price and Drevets, 2010).
3. Pathway-Specific Synaptic Function. Optogenetic
tools have also enabled the investigation of afferent-
specific synaptic neurotransmission and the input-
specific modulation of projection target activity during
behavior or paired with slice electrophysiology (Petreanu
et al., 2009; Stuber et al., 2011; Tye et al., 2011; Pascoli
et al., 2012). Pathway-specific synaptic neurotransmis-
sion at isolated efferent projection targets is necessary to
gain a complete functional understanding of any specific
brain region, which may differentially regulate down-
stream activity in a projection target-specific manner. In
brief, virally transduced neurons within a given brain
region achieve high opsin membrane insertion and
efficient trafficking that results in high expression levels
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throughout the soma and axon terminals (Gradinaru
et al., 2010). As a consequence, light delivery to fiber
terminals within projection targets will activate input-
specific synaptic transmission. This level of specificity is
necessary to determine the downstream physiologic or
behavioral effect of activity deriving from a common
circuit node, such as the basolateral amygdala (BLA),
which can vary in a target-specific manner and likely
depends on differential effects of specific inputs that
contribute to postsynaptic responses. Two recent studies
that used projection-specific targeting to study amygdala
function highlight how activity in one brain region may
mediate distinct behavioral responses depending on the
strength and pattern of activity that it communicates to
specific downstream targets (Stuber et al., 2011; Tye
et al., 2011). The amygdala is a critical structure for
processing negative emotions, such a fear (Fanselow and
Gale, 2003; Pare et al., 2004; Ehrlich et al., 2009;
LeDoux, 2012), but also plays an integral role in the
encoding and behavioral responses to salient environ-
mental cues of both negative and positive valence (Paton
et al., 2006; Ambroggi et al., 2008; Ishikawa et al., 2008;
Tye et al., 2008; Shabel and Janak, 2009; Gardner,
2011). Pathway-specific optogenetic modulation of the
glutamatergic projection from the BLA to the nucleus
accumbens (NAc), including the activation and inactiva-
tion of BLA terminals in the NAc, confirmed that this
circuitry is both necessary and sufficient for cue-driven
motivated behavior (Stuber et al., 2011). In a separate
study, a sophisticated project-targeting approach was
used to isolate the circuit between the BLA and the
central amygdala. Optical modulation of this pathway
bidirectionally influenced anxiety behavior in mice,
whereas activation of BLA cell bodies had no effect
(Tye et al., 2011). Taken together, these studies
demonstrate the strength of optogenetic methods to
reveal precise neuronal projections that are relevant to
neuropsychiatric disease.
III. Enhancing Circuit Specificity by Combining
Optogenetic and Pharmacological Approaches
The optogenetic approaches reviewed above have
already had a transformative effect on neuroscience
research. However, it is often necessary to integrate
multiple tools and/or approaches to achieve a more
comprehensive understanding of neural circuit func-
tion. Optogenetic tools, despite overcoming many
limitations of conventional methods, also have weak-
nesses that are beginning to be addressed with
innovative strategies. Below, we discuss two principal
strategies used to enhance the utility of optogenetics.
First, combining pharmacological manipulations with
optogenetic analysis in vivo and with slice physiology
has greatly extended the strength of either individual
approach. Second, novel approaches are extending the
power of optogenetics beyond alterations in membrane
physiology and control of spiking activity to selectively
probe cell function and biologic processes at the level of
signal transduction pathways, protein interactions,
and gene regulation.
The pairing of optogenetics with patch-clamp elec-
trophysiological techniques presents many possibilities
for integration with pharmacological manipulations to
enhance specificity for probing neural circuit mecha-
nisms. At a basic level, optogenetic activation of
genetically distinct cell types is already widely used
to characterize input -specific synaptic neurotransmis-
sion at various postsynaptic cells within a microcircuit
without perturbing the activity of other nearby non-
target cell types. Also, measuring the firing response of
a specific cell type to various light delivery protocols
(i.e., pulse trains of varying frequency, constant
stimulation intervals) will yield important information
for later targeting the same cell population during in
vivo behavioral manipulations and can reveal impor-
tant information about the electrical properties of that
given cell type. Both transgenic mouse lines and cell
type–specific promoters used in recombinant viruses
allow for targeted opsin expression to a neuronal
population defined by its neurotransmitter content
(Yizhar et al., 2011a). However, functionally defining
neuronal populations according to a single dimension,
such as neurotransmitter content, or distinct genetic
marker may be problematic. The neurotransmitters
glutamate and GABA are ubiquitous throughout the
nervous system, and often, their specific postsynaptic
effects are modulated by the coincident release of a
different chemical messenger (i.e., neurotransmitters,
neuropeptides, or hormones) from converging inputs.
The development of significantly red-shifted light-
gated opsins, such as C1V1, permits the selective
control of two input pathways to a postsynaptic target
that allow for testing of the combinatorial effect of
distinct inputs to a common projection source (Yizhar
et al., 2011a). This technology should help to determine
how pharmacological treatments, such as various
neurotransmitter receptor agonists or antagonists,
can differentially alter synaptic transmission in an
input-specific fashion. In addition to the convergence of
multiple chemical signals from distinct afferent path-
ways, single terminal fibers may corelease trans-
mitters or peptides. Neurotransmitter corelease has
been examined with optogenetics paired with slice
physiology. Two recent studies highlight this phenom-
enon by showing that activation of one set of geneti-
cally defined presynaptic inputs resulted in two
distinct neurotransmitter signaling events. Research
has indicated an important role for DA and glutamate
coincident signaling in a variety of motivated behav-
iors, including responding to motivationally significant
cues (Di Ciano et al., 2001; Phillips et al., 2003; Stuber
et al., 2008). The unsettled debate over possible glu-
tamate release from DA neurons was resolved using
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optogenetics to selectively stimulate ChR2-positive
DAergic terminals in the NAc shell, which resulted in
excitatory postsynaptic currents that could be abolished
by a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor antagonists (Stuber et al., 2010; Tecuapetla
et al., 2010), confirming that at least some midbrain DA
neurons are capable of coreleasing glutamate in the NAc.
Pharmacological blockade of DA receptors did not
significantly alter these glutamate-mediated currents,
indicating that the detected glutamate release events
were not attributable to polysynaptic signaling requiring
DA receptor activation within local NAc microcircuitry.
Integrating pharmacological and optogenetic manip-
ulations also allows for the dissection of complex local
microcircuitry, such as what is seen in the neocortex.
The use of subcellular ChR2-assisted circuit mapping
(sCRACM) illustrates the integrative application of
pharmacology and optogenetics to better understand
cortical microcircuits (Petreanu et al., 2009; Mao et al.,
2011). Cortical microcircuitry is exceedingly complex,
such that the functional effect of a synaptic input to
a single principal pyramidal neuron varies signifi-
cantly depending on its precise spatial location on the
dendrites or soma. In addition, because of the high
degree of recurrent excitatory collaterals within corti-
cal layers, it is often difficult to isolate monosynaptic
responses arising from the activity of a specific input.
sCRACM uses the pharmacological agents tetrodotoxin
to block Na+ channels and 4-aminopyridine to block K+
channels, in conjunction with ChR2 terminal stimula-
tion to isolate single monosynaptic glutamatergic
inputs. This technique was applied to the rodent
somatosensory cortex to map and define the functional
effect of isolated inputs to pyramidal neurons in
various layers of the cortex (Petreanu et al., 2009). Of
interest, synapses were observed to spatially segregate
according to the location of the structure providing the
input, a fact that could have significant consequences
for the induction of plasticity within cortical micro-
circuits. Thus, sCRACM combines the strengths of both
pharmacological and optogenetic manipulations to
more precisely map microcircuits, which may help to
reveal dysfunctional connectivity patterns that have
relevance for many neuropsychiatric and neurologic
disorders.
The application of optogenetic manipulations to in
vivo behavioral experiments has been a powerful
approach for testing the necessity and sufficiency of
activity in defined circuits for the production of a range
of behavioral responses (Adamantidis et al., 2011;
Letzkus et al., 2011; Stuber et al., 2011; Tye et al.,
2011; Knobloch et al., 2012; Stamatakis and Stuber,
2012; van Zessen et al., 2012). For example, research
has implicated both glutamatergic and dopaminergic
signaling in the NAc as critical mediators of motivated
behaviors (Di Ciano et al., 2001; Ambroggi et al., 2008;
Stuber et al., 2008). In vivo optogenetic circuit analysis
of the BLA to NAc glutamatergic pathway revealed
that selective optogenetic activation of BLA fibers in
the NAc was rewarding to mice and could reinforce
nose-poke behaviors to achieve further stimulation
(Stuber et al., 2011). To test whether coincident
dopamine was mediating the effect of BLA glutama-
tergic inputs on motivated behavioral responding, local
pharmacological administration of D1 and D2 receptor
antagonists into the NAc prior to optical stimulation
was performed and demonstrated that D1 receptor
activation was necessary for the BLA glutamate to
drive motivated behavior. This result underscores the
benefit of applying an integrative approach to the
analysis of neural circuit mechanisms and to enhance
the strengths of any single approach to study neural
function.
There are also important caveats and limitations
that arise with in vivo optogenetic behavioral manip-
ulations that can be addressed by pharmacological
means. One caveat to the optogenetic projection
targeting techniques arises because afferent fibers
exiting a structure are frequently bundled together,
and stimulating terminals in one region may also
stimulate fibers of passage that may also be expressing
opsins. For example, DA afferents from the VTA
projecting to the PFC travel through the NAc (Beck-
stead et al., 1979; Herbert et al., 1997), and stimulation
of DA terminals in the NAc will likely also stimulate
PFC-projecting fibers. Another limitation to this
method is the possibility of back-propagating action
potentials. Optical stimulation of terminals in one
region could trigger antidromic action potentials that
activate the cell bodies, which may then activate axon
collaterals projecting to other regions. This could in
theory lead to behavioral effects unrelated to the
specific input under investigation. This limitation can
be partially dealt with by microinjecting tetrodotoxin
or lidocaine in the cell bodies of the virally transduced
population of neurons to eliminate neural activity that
antidromically reaches the soma induced by terminal
stimulation (Stuber et al., 2011). Currently, an in-
tensive research effort is directed toward engineering
or identifying new virus variants that permit more
precise circuit mapping and control of activity in
circuits and avoid these nonspecific effects. These
alternative strategies typically exploit the ability of
many viruses to spread trans-synaptically in either the
anterograde or the retrograde direction, which will
enable a single circuit between two structures to
be selectively modulated without activating fibers
that exit the same structure but target another brain
area. Similar techniques involving a retrogradely
traveling canine-adenovirus engineered to express
Cre-recombinase have been used to restore dopamine
function only in specific VTA dopaminergic pathways
of dopamine-deficient mice and leave other dopamine
projections unaffected (Hnasko et al., 2006). Newer
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approaches involving modified herpes simplex virus or
pseudorabies are actively in development that enables
the expression of opsins or reporters only in precise
neural circuits (Neve et al., 2005; Hnasko et al., 2006;
Robinson et al., 2007; Callaway, 2008; Osakada et al.,
2011). Sophisticated advances such as these will
inevitably lead to even more precise targeting of neural
circuits for controlling neuronal activity or manipula-
tion of gene and protein function.
IV. Optical Control of Intracellular
Signaling Processes
Currently, optogenetic manipulations provide the
best method for the spatiotemporal control of neuronal
activity or presynaptic terminal neurotransmitter re-
lease in circuits, but the functional consequences of
optical activation in downstream postsynaptic circuit
elements remain largely undefined. Most opsins
modulate neural activity by directly controlling ion
conductance across the membrane, which leads to
depolarization or hyperpolarization and a respective
increase or silencing of spiking activity (Zhang et al.,
2006; Fenno et al., 2011; Yizhar et al., 2011a).
However, the pattern of action potential firing within
discrete time intervals is only one aspect of the
dynamic process of neural circuit function. Endogenous
neural circuit activity also requires neurotransmitter
release, postsynaptic receptor activation, the initiation
of second messenger signaling cascades, protein-
protein interactions, and ultimately, changes in pat-
terns of gene expression. These intracellular processes
that are associated with the endogenous circuit-level
activity have not been amenable to study with
optogenetic tools. Ongoing research aims to achieve
an equivalent level of cell type and circuit specificity as
optogenetic approaches for the selective manipulation
of intracellular protein interactions and gene tran-
scription processes (Kennedy et al., 2010; Wang et al.,
2012). These technical advances may eventually aid in
the identification of dysregulated postsynaptic intra-
cellular mechanisms that contribute to maladaptive
behaviors and the manifestation of disease states. As
a whole, the combined application of these tools should
broaden our understanding of the mechanistic under-
pinnings of neuropsychiatric disorders at multiple
levels.
A novel class of synthetic genetically encoded optical
tools, the optoXRs, which are chimeric proteins coupled
to different intracellular G-protein–initiated signaling
cascades, allow for G-protein receptor–initiated bio-
chemical pathway activation in vivo (Airan et al., 2009;
Zhang et al., 2010) (Fig. 2). In a study by Airan et al.
(2009), two optoXR receptors with distinct postsynaptic
signaling consequences were designed: one coupled to
a b2-adrenergic initiated Gs cascade that lead to
increased cyclic AMP levels and a second that coupled
to an a1-adrenergic initiated Gq cascade that resulted
in increased inositol trisphosphate and diacylglycerol
levels. The behavioral consequences of precisely timed
photoactivation of these signaling pathways within the
NAc were tested in a place conditioning paradigm by
pairing optical activation with one chamber on one day
and quantified preference as mice freely explored the
entire chamber the following day. Of interest, mice
formed a significant preference for the stimulated
chamber when the optoXR coupled to a1 was stimu-
lated. Although early in development, these optical
tools for modulating biochemical signaling pathways
with cell- and pathway-specific precision are promising
methods for interrogating neural circuit function
beyond the level of spiking activity and to identify
dysregulated intracellular processes that contribute to
disease. Thus, we expect these and similar studies to
provide critical information to guide the identification
of molecular targets for novel small molecule
pharmacotherapies.
Both neuropsychiatric disease states and optogenetic
circuit manipulations to induce behavioral phenotypes
undoubtedly involve altered intracellular pathways and
require protein interactions, but the technology to
selectively manipulate these protein-protein interac-
tions and test their functional consequences has only
just become available (Kennedy et al., 2010; Wang et al.,
2012). Recent strategies have been devised that use
genetically encoded dimerizers from plant photorecep-
tors and exploit the spatiotemporal precision of light to
control protein-protein interactions. Initial demonstra-
tions of these tools, such as those using the light oxygen
voltage domain of Arabidopis thaliana (Wu et al., 2009)
demonstrated proof of concept but suffered from slow
light-activated kinetics or irreversibility of dimerization
after light induction (Kennedy et al., 2010). Newer
systems have been designed on the basis of dimerization
modules of the basic helix-loop-helix protein Arabidop-
sis CIB1 and cryptochrome 2. This system can induce
protein-protein dimerization after blue light stimulation
with subsecond time and subcellular spatial resolution
(Fig. 2). These properties were exploited to induce
various biologic processes, including protein transloca-
tion and transcription in mammalian and yeast cells.
The continued improvement of this technology will
eventually permit intracellular signaling cascades
within genetically defined cell types and pathways to
be selectively modulated to test the contribution of
alterations in specific protein function for the develop-
ment of disease states.
Ultimately, for neuronal circuit activity to translate
into long-term behavioral consequences, gene function
must be altered in specific neuronal populations and
pathways. Intracellular signaling cascades that are
initiated by ligand-receptor interactions at the mem-
brane and involve protein interactions, which can now
be selectively manipulated with light, often result in
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changes in neuronal gene transcription. Activity-dependent
changes in neuronal structure and function, which are
the proposed neural mechanisms of learning and
memory, are dependent on changes in gene regulation.
Just as light-gated opsins have allowed for precise
manipulation of electrical activity within defined circuits
to test function, a tool for precise spatiotemporal control
of gene expression within specific pathways would
permit the systematic analysis of the effect of selective
changes in gene function on behavior. Very recently,
light-switchable transgene systems have been designed
and implemented that exploit the spatiotemporal spec-
ificity of light to selectively trigger changes in gene
function within specific cell types. One system, named
LightOn, capitalized on the light dimerization property
of Vivid, a light oxygen voltage domain containing
protein, to form a synthetic light-switchable gene-
promoter system. This transactivator was shown to bind
promoters after blue light exposure and to rapidly
initiate transcription of target transgenes in both
mammalian cells and mice (Wang et al., 2012). LightOn
and other systems that allow for precise spatiotemporal
control of genes in a cell type–specific fashion with light
are promising new tools for testing causal relationships
between specific alterations in cellular processes and the
manifestation of pathologic behavioral phenotypes (Fig.
2). However, it is important to highlight that these new
optical approaches for controlling protein-protein inter-
actions and gene transcription are still in the early
stages of development. As with any new technique,
a rigorous analysis of these new methods must be
conducted to ensure that introduction of light-activated
protein products or genes is not disruptive or toxic to
normal cellular function. Nevertheless, we suggest that
the potential benefits of selectively isolating and
manipulating key components of signaling or gene
Fig. 2. Optogenetic modulation of postsynaptic neuronal function at multiple levels of cellular activity. (A) Synthetic light-gated receptors, such as the
OptoXR’s, are coupled to G-protein signaling cascades that alter postsynaptic function by activating intracellular second-messenger cascades that may
lead to alterations in neuronal excitability. (B) Light-inducible protein dimerizers will permit the selective control of intracellular signaling cascades
and other diverse cellular processes with subsecond temporal resolution and subcellular spatial resolution through light activation of protein-protein
interactions. (C) Light-switchable transgenes will permit the selective control of target gene expression within genetically defined neuronal populations
to test the causal role of gene activation on various behaviors. Shown in the figure is a schematic of the LightOn gene expression system, which involves
light-induced homodimerization of GAVP, which then interact with upstream UASG promoter elements to initiate the transcription of a gene of
interest.
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transcription cascades that may reveal novel drug
targets outweighs the initial challenge posed during
refinement and optimization of a new technique.
V. The Future: Establishing Causal Relationships
Between Neural Circuit Activity and Cell
Type–Specific Changes in Gene Transcription
The dominant paradigm for understanding the genetic
basis of psychiatric disorders has been to identify
candidate gene polymorphisms through genome-wide
analysis studies of clinical or at-risk populations that
may be associated with the development of these
diseases (Marian, 2012). Although there have been
notable successes from this approach, the experimental
process is laborious, and the candidate genes often
explain very little of the variance in susceptibility and
are correlative, not causal, in nature. We propose, as
a complement to this top-down approach, an alternative
strategy that takes a bottom-up approach that begins
with optogenetic circuit activity perturbations followed
by transcriptional sequencing to identify many candidate
genes and potentially protein targets in a high-
throughput, massively parallel fashion. Fundamentally,
these two approaches underscore the more complex issue
of whether the neural circuit alterations underlying
neuropsychiatric and neurologic disorders arise from
pathologic neural processing associated with aberrant
experiences or whether genetic variants and predisposi-
tions play a greater causal role in their development. In
reality, genetic factors, environmental experiences, and
gene-environment interactions all synergistically contrib-
ute to the development of these complex disorders.
However, the technological advances of optogenetics
and other fields have provided a mechanism for
selectively disrupting neural circuit activity at key circuit
nodes to induce changes in gene expression.
The research strategy that we outline here dovetails
well with advances and reduced costs of high-throughput
sequencing. The critical gap that can be addressed with
an integrative optogenetic-transcriptomics approach is
how to translate the important research findings
enabled by optogenetics regarding cell type– and
pathway-specific neural function in mediating behav-
iors relevant to psychiatric disorders and expand on
this information to produce data with real potential to
inform the development of better treatments for these
disorders.
An integrative optogenetic-transcriptomics approach
may reveal novel candidate genes and, thus, proteins
that are dysregulated after experimentally adminis-
tered changes in neural circuit activity. The tran-
scriptome, which is broadly defined as the entire RNA
contents of a cell, is a dynamic feature of specific cell
types that mechanistically serves to translate genotype
information into an adaptive phenotype (Tang et al.,
2011). Changes in cellular function that occur across
development, in response to environmental stress, and
with the development of disease states are all
mediated by transcriptome alterations and changes
in gene function. For this reason, investigating the
transcriptome of targeted cell types within dysregu-
lated neural circuits is likely to produce important
insights into altered cellular function underlying
disease. In addition, a logical extension of the pharma-
cogenomics effort that has been evolving in parallel is
the effort in molecular genetics and nanotechnology to
devise strategies for the delivery of more highly
targeted, cell-specific small molecules that act pre-
cisely at the locus of dysfunction (Zhang et al., 2009;
Paulo et al., 2011; Tian et al., 2012). It is within
these current trends that we envision optogenetics
being applied most innovatively for the identification
of candidate genes and proteins within specific neuronal
populations and circuits that subsequently can be targeted
with cell-specific small molecule pharmacotherapies.
Our aim from the following research approach is not
to provide a detailed experimental protocol but to
present a flexible roadmap for guiding the implemen-
tation of similar studies (Fig. 3). However, we hope it
will serve as a useful reference and to stimulate ideas
for applying optogenetics toward the elucidation of
novel cell- and circuit-specific mechanisms and for the
identification of candidate genes to target with new
selective pharmacotherapies. For clarity, we have
subdivided the discussion into the following three
sections that specifically address a different stage of
the experimental process: 1) neural circuit selection
and optogenetic investigation in animal models, 2)
application of transcriptome sequence technologies to
identify dysregulated gene and potentially protein
targets associated with pathologic state, and finally,
3) the development of small molecule pharmacological
agents to target candidate gene/protein function with
cell and circuit specificity.
A. Circuit Selection and Optogenetic Interrogation
Although we present our approach as bottom-up to
emphasize that the direction of the process contrasts
that of the more conventional approach of first
identifying single genetic polymorphisms, some top-
down information about neural circuits that have been
implicated in neuropsychiatric disorders is necessary
to guide the selection of pathway to study. One
conceptual hypothesis about the origin of many
neuropsychiatric disorders that may guide circuit
selection is that these diseases arise from altered
function in limbic brain structures and circuits that
process reward and aversion or in the cortical regions
that provide top-down control of these processes (Kim
et al., 2011). An extensive body of research has
amassed within the past decade that has used
functional magnetic resonance imaging on healthy
and clinical populations and serves as an invaluable
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Fig. 3. Optogenetic-transcriptomics approach to identify neural circuit-specific dysregulated genes or proteins that may be future therapeutic targets
for the treatment of neuropsychiatric disorders. Target identification steps are described as follows: 1) optogenetic analysis of function within a specific
neural pathway followed by the harvesting of postsynaptic cell contents to be subject to transcriptome analysis; 2) sample preparation involving the
isolation of postsynaptic RNA, reverse transcription to cDNA library, and subsequent amplification; and 3) high-throughput RNA-seq analysis to
identify and measure all transcripts within a specific cell to be followed by sophisticated bioinformatics analysis to identify which gene and protein
levels have been altered by optogenetic circuit activation. Target validation steps as follows: 4) after RNA-seq analysis and target identification, results
should be verified through brain tissue collection and protein or gene analysis with Western blot, quantitative polymerase chain reaction, or histologic
methods; 5) target gene or protein function should be validated in vivo through viral-mediated overexpression or knockdown of target gene to reverse
the behavioral effect of optogenetic circuit manipulation; and 6) development of small-molecule pharmacotherapy to target dysregulated gene or
protein function within the affected cell population to restore normal cellular and behavioral function.
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resource to guide research design and the selection of
a clinically relevant neural circuit to investigate
(Linden and Thome, 2011; Linden, 2012). Significant
methodological and analytic advancements have en-
abled better assessment of global resting-state activity
and measures of regional and functional connectivity
and have produced vital circuit-level information in
healthy and various clinical populations (Raichle and
Snyder, 2007; Raichle, 2010; Pan et al., 2011). For
simplicity, we limit the discussion to one prominent
neural circuit connecting the amygdala and the pre-
frontal cortex. This pathway has been heavily impli-
cated in a range of psychiatric disorders that span the
spectrum, such as mood and anxiety related, addiction,
autism, schizophrenia, and other cognitive disturban-
ces (Bishop, 2007, 2008; Koob and Volkow, 2010; Price
and Drevets, 2010; Shin and Liberzon, 2010). In
addition, a concerted effort has been made to unify
the vast knowledge acquired from animal research into
the neural mechanisms of fear conditioning and
extinction and the human psychology study of fear
(Milad and Quirk, 2012), which has sharpened our
understanding of the neural basis of anxiety- and fear-
related disorders. In general, functional magnetic
resonance imaging studies have identified a disrupted
balance in activity between the prefrontal cortex and
amygdala that is associated with anxiety. Specifically,
this disruption is observed as a hyperactive amygdala
and hypoactive prefrontal cortex that manifests
behaviorally as an increased threat responsivity and
diminished capacity for regulating emotional res-
ponses (Bishop, 2007, 2008). These findings fit well
with the extensive body of research into the neural
circuit mechanisms of associative fear conditioning and
extinction processes, which have established the
amygdala as the key neural structure for learning
associations between cues and aversive outcomes and
infralimbic regions of the medial prefrontal cortex for
suppressing conditioned fear responses after extinction
training (Quirk and Beer, 2006; Quirk and Mueller,
2008; Sotres-Bayon and Quirk, 2010). The choice of
neural circuit to investigate will affect all subsequent
stages of the experimental procedure and will likely
determine the therapeutic potential of any candidate
proteins identified for drug targeting.
The next stage of the approach entails a complete
optogenetic analysis of the selected pathway involving
slice physiology and in vivo circuit manipulations
during various behavioral assays. Here, the goal is to
successfully recapitulate some of the behavioral fea-
tures of the focal psychiatric disorder using as many
validated and established behavioral assays as is
feasible. Next, the choice of cell type to target and
the strategy, either the promoter specific or transgenic
approach, for achieving cell type–restricted opsin
expression must be made (see Yizhar et al., 2011a;
Tye and Deisseroth, 2012, for comprehensive review of
opsin targeting strategies and issues of experimental
design). Because glutamatergic pyramidal projection
neurons are known to strongly express the enzyme
calcium-calmodulin kinase 2a and are the main output
projection neurons in both the BLA and the medial PFC,
viral gene expression tied to the calcium-calmodulin
kinase 2a promoter would be a suitable approach for
investigating glutamatergic inputs in either direction of
this reciprocal circuit. Next, the pathway should be
characterized in accordance with firing properties and
synaptic function with use of optogenetic manipulations
paired with brain slice electrophysiology to gain an
understanding of the electrical properties of neurons in
the pathway and to inform the choice of stimulation
parameters for behavioral manipulations. Many vali-
dated and well-established paradigms for measuring
behavior relevant to amygdalocortical function are
available, including open-field assessment of locomotor
and anxiety behavior, cued and contextual fear condi-
tioning, conditioned place preference, elevated plus-
maze, and social interactions. Of importance, all are
easily interfaced with the necessary hardware and
software for performing in vivo optogenetic manipula-
tions (Zhang et al., 2010; Sparta et al., 2012). With use
of a range of stimulation parameters and behavioral
metrics, the detailed assessment of the symptoms of an
anxious phenotype should be performed. This should be
validated in a range of tests that may include
optogenetic activation or inhibition time-locked to
aversive events, cues that predict them, or long- or
short-term stimulation to induce place aversion or other
characteristic symptoms of an anxious phenotype.
B. Candidate Gene Search Using High-Throughput
Genome Sequencing Methods
In recent years, the methods for genomic sequencing
and transcriptome analysis have improved exponen-
tially in their power and specificity to measure gene
expression with a high degree of cellular resolution
(Tang et al., 2011). It is now possible to catalog all
species of RNA within a single cell with is of powerful
next generation RNA-sequencing technologies (RNA-
seq), which will allow sophisticated and quantitative
analysis of gene expression within specific cell types
after different environmental exposures or disease
states (Wang et al., 2009). The next stage of the
approach exploits the strength of optogenetics to
identify and functionally characterize neural circuits
and combines it with the genetic specificity of next-
generation sequencing technologies to identify disrup-
ted gene expression patterns after experimental en-
hancement or reduction in pathway-specific neural
activity. The inherent complexity of mental disorders,
which undoubtedly depend on the interaction of many
genes and biologic pathways with environmental cir-
cumstances to manifest as a phenotype, necessitates
that a fully integrative approach be applied to
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deciphering these complicated disorders. Of importance,
a key strength of this integrative approach comes from
being nonbiased and not guided by expectations about
potential candidate genes. Instead, the approach is
driven by behavioral observations of pathologic pheno-
types induced by circuit-specific optogenetic activation
of precise neural pathways. These behavioral observa-
tions inform the subsequent sequencing stage, whereby
we attempt establish causal relationships between
evoked activity in a neural pathway and changes in
gene transcription induced by the pathologic activation
state. Ultimately, any candidate genes identified by
sequence analysis need to be validated to determine
whether restoring their expression to normal levels
affects neural circuit activity and reverses the negative
behavioral phenotype. Rigorous experimenter control is
essential to ensure that the measured changes in gene
transcription are the result of optogenetic activity
manipulations and not preexisting differences that
may confound the interpretation of the data.
After optogenetic pathway-specific stimulation, two
primary options are available for tissue samples
collection: large tissue punches encompassing an entire
brain region or single cell collection of specific cell types
or cells that are integrated within a specific microcir-
cuit. Single cell resolution is preferable but may not be
attainable in all circumstances. Quantification of global
patterns and changes in gene expression in a target
area after optogenetic stimulation is a viable first pass
alternative for the identification of dysregulated genes.
Three main techniques are available for achieving
single cell resolution. First, fluorescent activated cell
sorting is a well-established tool to separate cells by
type according to level of fluorescent marker expression;
however, this method is optimal for cells in culture but
can be less effective for collecting neurons in brain
tissue. Second, laser capturemicrodissection is a feasible
option for collection of single cells for analysis of mRNA
expression. The laser capture microdissection procedure
does involve some chemical staining that can potentially
affect the quality of the obtained mRNA, but it is
usually sufficient for quantitative transcriptome analy-
sis (McCullumsmith and Meador-Woodruff, 2011). The
third option involves harvesting whole cell mRNA
during patch clamp electrophysiology by extracting the
contents of the patched cell and then applying sequenc-
ing technologies to amplified mRNA (Citri et al., 2012).
This option is especially attractive, because the precise
details of each cell’s anatomic position within the target
region will be known, which is of great importance in
the cortex. As mentioned, the mammalian cortex has
a highly stereotyped laminar cytoarchitecture, with
each layer being populated by specific cell types that
have clearly defined functional roles and patterns of
efferent and afferent connections. Therefore, the possi-
bility exists that the cortical dysfunction underlying
various neuropsychiatric disorders may involve changes
in processing that are more associated with a specific
layer or cell type in one layer. Therefore, it is important
that single cell resolution be achieved for gene expres-
sion analysis to determine whether input-specific
activity alters transcription in a layer-specific fashion.
The recommended method for whole-transcriptome
analysis is the next-generation RNA-seq. RNA-seq has
many advantages over older methods of transcriptome
analysis, such as hybridization-based approaches and
microarray technology. The major limitations of these
traditional methods are that they depend on existing
knowledge of the genome sequence, they have high
background because of cross-hybridization, and the
expression data are difficult to compare across studies
(Wang et al., 2009). RNA-seq methods have the major
advantage of requiring less starting material, which is
ideal for single-cell analysis. In addition, this method is
not limited by known genomic sequence data and, thus,
provides a whole transcriptome analysis that detects
both coding and noncoding regulatory RNAs, which could
be involved in the pathologic mechanisms of various
psychiatric disorders. Of most importance, with RNA-
seq, the actual nucleotide sequence is determined, which
allows for the detection of single nucleotide polymor-
phisms and alternative gene isoforms. An obvious caveat
arising from these advantages is that the number of
identified splice variants may be extensive, which could
make subsequent bioinformatic analyses more challeng-
ing and may necessitate that complementary studies be
performed using microarrays. Furthermore, the issue of
defining a normal pattern of expression to serve as
a baseline comparison for any observed transcriptional
changes assessed by RNA-seq can become challenging.
However, with our proposed approach, a control group
that does not receive optical stimulation of the target
pathway will always serve as a comparison condition.
Despite these limitations, applying RNA-seq technology
is likely to be the best strategy for identifying changes in
gene function in a specific cell type of a neural circuit in
which dysfunction is implicated in a neuropsychiatric
disorder. After RNA-seq and the identification of
candidate genes in which the function changes after
optogenetic stimulation of the target neural circuit, it is
advisable to validate the results with more traditional
methods, such as quantitative polymerase chain reaction
analysis, in situ hybridization to measure mRNA within
brain sections, Western blots, or immunohistochemistry.
C. Cell Type and Circuit Selective Small Molecule
Pharmacotherapies as Novel Treatments for
Psychiatric Disorders
Targeted drug delivery to a specific site of action has
the profound advantage of maximizing therapeutic
efficiency and minimizing systemic toxicity and off-
target effects, which is of great importance in the
treatment of any disease. Disorders of brain function
present a great challenge for treatment because of the
Integrating Optogenetic Pharmacological Approaches 167
extreme structural complexity and cellular heterogene-
ity of the nervous system. The final stage of the
experimental approach aims to achieve the ultimate
goal of developing novel pharmacotherapies that act
with cell type and pathway specificity to restore normal
cell function by targeting those genes that were found to
be dysregulated during the RNA sequencing stage. The
true potential for this stage of the experimental
approach depends on the continued technological
advancement is several fields that are intensely focused
on developing novel methods for delivering small
molecules to disrupt some aspect of cellular function
in a cell-specific manner. Although the goal of small
molecule delivery to specific cell populations to modu-
late intracellular function is being approached from
a variety of angles, here, we discuss two strategies for
targeted drug development: nanoparticles for intracel-
lular drug delivery and selective enzyme substrate
pairs, both of which hold great potential for the future
treatment of neuropsychiatric disorders.
The possibility for nanotechnology to revolutionize
pharmaceutical development is currently generating
great enthusiasm among scientists and the general
public. The initial impetus for the field of nanoparticles
for delivery of small molecules emerged from prom-
inent failures in gene therapy clinical trials and the
realization that synthetic methods for intracellular
delivery of DNA needed to be developed (Paulo et al.,
2011). Nanotechnology has permitted the development
of nanocarriers that can encapsulate drugs, proteins,
nucleic acids, or vaccines for strategic delivery to
various diseased tissue and cellular targets (Morachis
et al., 2012). A variety of materials, with their res-
pective advantages and drawbacks, have been used for
nanocarrier design, including lipids, inorganic materi-
als, and polymeric systems (Morachis et al., 2012). This
rapidly evolving field currently has the capability to
produce a variety of nanocarriers that can deliver
small interfering RNAs, proteins, and small molecules
to different intracellular regions, which has important
implications for cancer therapeutics, stem cell differ-
entiation, and therapeutic medicine (Paulo et al.,
2011). To date, nanotechnology has not produced
a means to target a precise genetically distinct cell
type in the nervous system, but the methods for
achieving specificity are rapidly evolving. For example,
the surface of nanoparticles has been conjugated with
specific ligands or antibodies to permit their binding to
cell types expressing the complementary receptor, and
subsequently, the drug contents can be endocytosed for
action within the cell. One achievement of nanoparticle
technology with great relevance for the treatment
of neuropsychiatric disorders has been the use of
antibody-conjugated nanoparticles to overcome the
blood-brain barrier defense of the brain (Aktas et al.,
2005). The blood-brain barrier has posed a persistent
challenge for the pharmacological treatment of brain
disorders, because this system of tight junctions
between endothelial cells is extremely effective at
restricting most proteins and small molecules from
entering the brain (Morachis et al., 2012). The use of
nanoparticles for intracellular delivery of small mole-
cules is still in its infancy but is likely to transform the
pharmaceutical industry and have an immense impact
of the future treatment of neuropsychiatric disorders.
A second promising approach for delivery of cell-
specific small molecule drugs exploits the interaction of
enzyme-substrate pairs to achieve cell specificity. The
underlying principle of this strategy is to mask a small
molecule drug by the attachment of a cleavable block-
ing functional group that renders it unreactive to
endogenous cellular enzymes but is easily removed by
a specific exogenous enzyme (Zhang et al., 2009; Tian
et al., 2012). Cell type specificity is achieved by the
expression of this exogenous enzymatic protein within
a target cellular population where cleavage of the pro-
drug will occur and its therapeutic effect may be
somewhat restricted. If optogenetic circuit analysis and
RNA-seq identify a specific gene product that may
perform an integral role in cellular signaling, thera-
peutics to inhibit or restore gene function or associated
intracellular signaling modalities can then be de-
signed. The technology for targeting genetically de-
fined cells with small molecule drugs to restore normal
functioning was demonstrated by a recent study from
Tian et al. (2012) that identified a specific ester-
esterase pair that could be used to deliver active small
molecules to precisely defined cell types. The specific
pair of porcine liver esterase (PLE) and a a-cyclopropyl
ester was highly efficient at unmasking the small
molecule and had negligible reactivity with endoge-
nous esterases. Of most importance, this ester-esterase
strategy was used to deliver the pharmacological agent
monastrol in a cell-specific manner. Monastrol acts to
inhibit a component of the mitotic motor and, thus,
disrupts cell division, which produces a clear pheno-
type that can be used to assess the efficacy of the
targeted drug delivery. HeLa cells that were either
transfected with the exogenous esterase PLE (PLE+) or
not transfected (PLE2) were incubated with the ester
conjugated pharmacological agent and tested to de-
termine the efficacy of the targeted drug delivery. Of
importance, it was found that PLE+ cells displayed
significantly more spindle disruptions, which indicated
that the cell-specific targeting was successful. This
elegant study offers a clear demonstration that the
development of a generalizable cell-specific delivery
strategy for small molecule pharmacotherapies is within
reach. An obvious caveat to the application of this
method to humans is the necessity for gene therapy or
other mechanisms to introduce and express the exoge-
nous esterase for unmasking the pharmacological agent.
Although this will entail some risk, we feel it should
not deter the effort to develop novel cell-specific
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pharmacotherapies or which the benefits are certain to
outweigh any minimal risk that they carry. At present
and likely in the future, the methods for achieving cell
specificity inevitably entail some genetic manipulation;
however, as technology and scientific understanding
evolve, the prospect for bringing cell-specific pharmaco-
therapies into wide clinical use may become a reality and
the safety of these currently highly experimental
strategies will inevitably improve. The safety of gene
therapy for clinical application is currently an area of
active research. For example, recent studies with the
adeno-associated virus serotype 9 (AAV9) have reported
good distribution and transduction of the AAV9 vector in
nonhuman primate central nervous system tissue. Of
importance, for safety concerns, AAV9 delivery to the
cerebral spinal fluid did not shield against AAV anti-
bodies (Samaranch et al., 2012). Another effort that
promises to improve safety and potential for cell-specific
pharmacotherapies to achieve ready use in clinical
settings is the Pleiades Promoter Project. This interdis-
ciplinary research endeavor has used genome-wide
bioinformatic databases to analyze genes with brain
expression patterns of interest to inform the design of
compact MiniPromoters that can drive gene expression
in specific cell types and brain regions (Portales-
Casamar et al., 2010). The stated goal of this research
effort is to provide a publicly available resource to
facilitate research on brain development and therapies
and should prove to be an invaluable starting point for
designing versatile and safer pharmacotherapies that act
cell and circuit specifically in the central nervous system.
VI. Conclusions
The overview and future research directions that we
have presented here for pairing of optogenetic circuit
analysis with current and next generation pharmaco-
logical approaches reveal how novel cellular pathophys-
iological mechanisms underlying psychiatric disorders
can be uncovered. The current trend in biomedical
research and the demands imposed by new technologies
that require diverse technical expertise and produce
enormous data sets inevitably leads to a climate in
which integrative and collaborative approaches from
diverse disciplines are required. Current research is still
in the very early stages of developing and implementing
multidisciplinary approaches for the treatment of
complex brain disorders, but unparalleled potential is
certainly apparent as revolutionary tools, such as those
discussed here, contribute to the future.
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